Wnt signaling in bone formation and its therapeutic potential for bone diseases

The Wnt signaling pathway plays an important role not only in embryonic development but also in the maintenance and differentiation of the stem cells in adulthood. In particular, Wnt signaling has been shown as an important regulatory pathway in the osteogenic differentiation of mesenchymal stem cells. Induction of the Wnt signaling pathway promotes bone formation while inactivation of the pathway leads to osteopenic states. Our current understanding of Wnt signaling in osteogenesis elucidates the molecular mechanisms of classic osteogenic pathologies. Activating and inactivating aberrations of the canonical Wnt signaling pathway in osteogenesis results in sclerosteosis and osteoporosis respectively. Recent studies have sought to target the Wnt signaling pathway to treat osteogenic disorders. Potential therapeutic approaches attempt to stimulate the Wnt signaling pathway by upregulating the intracellular mediators of the Wnt signaling cascade and inhibiting the endogenous antagonists of the pathway. Antibodies against endogenous antagonists, such as sclerostin and dickkopf-1, have demonstrated promising results in promoting bone formation and fracture healing. Lithium, an inhibitor of glycogen synthase kinase 3β, has also been reported to stimulate osteogenesis by stabilizing β catenin. Although manipulating the Wnt signaling pathway has abundant therapeutic potential, it requires cautious approach due to risks of tumorigenesis. The present review discusses the role of the Wnt signaling pathway in osteogenesis and examines its targeted therapeutic potential.

[1]  真田 昌 骨髄異形成症候群のgenome-wide analysis , 2013 .

[2]  Kunihiro Matsumoto,et al.  A histone lysine methyltransferase activated by non-canonical Wnt signalling supresses PPAR-γ transactivation , 2012, Nature Cell Biology.

[3]  M. Fischer,et al.  Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors , 2012, Proceedings of the National Academy of Sciences.

[4]  E. Nemoto,et al.  Wnt5a signaling is a substantial constituent in bone morphogenetic protein-2-mediated osteoblastogenesis. , 2012, Biochemical and biophysical research communications.

[5]  Hans Clevers,et al.  Wnt/β-Catenin Signaling and Disease , 2012, Cell.

[6]  Paul Polakis,et al.  Wnt signaling in cancer. , 2012, Cold Spring Harbor perspectives in biology.

[7]  E. Tobiasch,et al.  Mechanisms Underlying the Osteo- and Adipo-Differentiation of Human Mesenchymal Stem Cells , 2012, TheScientificWorldJournal.

[8]  O. MacDougald,et al.  Wnt6, Wnt10a and Wnt10b inhibit adipogenesis and stimulate osteoblastogenesis through a β-catenin-dependent mechanism. , 2012, Bone.

[9]  C. Deng,et al.  TGF-β and BMP Signaling in Osteoblast Differentiation and Bone Formation , 2012, International journal of biological sciences.

[10]  Jennifer J Westendorf,et al.  Update on Wnt signaling in bone cell biology and bone disease. , 2012, Gene.

[11]  L. Kwak,et al.  Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma. , 2012, Blood.

[12]  K. Hankenson,et al.  Integration of BMP, Wnt, and notch signaling pathways in osteoblast differentiation , 2011, Journal of cellular biochemistry.

[13]  P. Kostenuik,et al.  Dickkopf‐1 regulates bone formation in young growing rodents and upon traumatic injury , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[14]  J. Goeman,et al.  Inhibition of Gsk3β in cartilage induces osteoarthritic features through activation of the canonical Wnt signaling pathway. , 2011, Osteoarthritis and cartilage.

[15]  D. Geschwind,et al.  Genome-Wide Analysis of a Wnt1-Regulated Transcriptional Network Implicates Neurodegenerative Pathways , 2011, Science Signaling.

[16]  Antara De,et al.  Wnt/Ca2+ signaling pathway: a brief overview. , 2011, Acta biochimica et biophysica Sinica.

[17]  P. Aspenberg,et al.  Anti-sclerostin antibody and mechanical loading appear to influence metaphyseal bone independently in rats , 2011, Acta orthopaedica.

[18]  Robert V Farese,et al.  Functional Genomic Analyses Identify Pathways Dysregulated by Progranulin Deficiency, Implicating Wnt Signaling , 2011, Neuron.

[19]  D. Kimmel,et al.  A Rate-Limiting Role for Dickkopf-1 in Bone Formation and the Remediation of Bone Loss in Mouse and Primate Models of Postmenopausal Osteoporosis by an Experimental Therapeutic Antibody , 2011, Journal of Pharmacology and Experimental Therapeutics.

[20]  G. Stein,et al.  Effects of miR‐335‐5p in modulating osteogenic differentiation by specifically downregulating Wnt antagonist DKK1 , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  F. Mseeh,et al.  Lrp5 functions in bone to regulate bone mass , 2011, Nature Medicine.

[22]  Xu Li,et al.  Proepithelin Stimulates Growth Plate Chondrogenesis via Nuclear Factor-κB-p65-dependent Mechanisms* , 2011, The Journal of Biological Chemistry.

[23]  P. Aspenberg,et al.  The effects of Dickkopf-1 antibody on metaphyseal bone and implant fixation under different loading conditions. , 2011, Bone.

[24]  D. Lacey,et al.  Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[25]  T. Rachner,et al.  Osteoporosis: now and the future , 2011, The Lancet.

[26]  P. Croucher,et al.  Glycogen synthase kinase‐3α/β inhibition promotes in vivo amplification of endogenous mesenchymal progenitors with osteogenic and adipogenic potential and their differentiation to the osteogenic lineage , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[27]  E. Posvar,et al.  Single‐dose, placebo‐controlled, randomized study of AMG 785, a sclerostin monoclonal antibody , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[28]  Linheng Li,et al.  Noncanonical Wnt signaling in vertebrate development, stem cells, and diseases. , 2010, Birth defects research. Part C, Embryo today : reviews.

[29]  P. Kostenuik,et al.  Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[30]  Tao Wang,et al.  miR-27 promotes osteoblast differentiation by modulating Wnt signaling. , 2010, Biochemical and biophysical research communications.

[31]  D. Kimmel,et al.  Generation and Selection of Novel Fully Human Monoclonal Antibodies That Neutralize Dickkopf-1 (DKK1) Inhibitory Function in Vitro and Increase Bone Mass in Vivo , 2010, The Journal of Biological Chemistry.

[32]  J. Zwerina,et al.  Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression , 2010, Annals of the rheumatic diseases.

[33]  David E. Komatsu,et al.  Modulation of Wnt signaling influences fracture repair , 2010, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[34]  T. P. Rao,et al.  An updated overview on Wnt signaling pathways: a prelude for more. , 2010, Circulation research.

[35]  Yonghe Li,et al.  Dkk1 Stabilizes Wnt Co-Receptor LRP6: Implication for Wnt Ligand-Induced LRP6 Down-Regulation , 2010, PloS one.

[36]  Jian Q. Feng,et al.  Granulin epithelin precursor: a bone morphogenic protein 2‐inducible growth factor that activates Erk1/2 signaling and JunB transcription factor in chondrogenesis , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[37]  J. Rubin,et al.  β‐Catenin—A supporting role in the skeleton , 2010, Journal of cellular biochemistry.

[38]  Daniel J Lightwood,et al.  Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[39]  K. Lyons,et al.  Wnt10b Deficiency Results in Age-Dependent Loss of Bone Mass and Progressive Reduction of Mesenchymal Progenitor Cells , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[40]  X. Zi,et al.  Wnt Inhibitory Factor 1 Decreases Tumorigenesis and Metastasis in Osteosarcoma , 2010, Molecular Cancer Therapeutics.

[41]  Di Chen,et al.  BMP‐2 modulates β‐catenin signaling through stimulation of Lrp5 expression and inhibition of β‐TrCP expression in osteoblasts , 2009, Journal of cellular biochemistry.

[42]  Y. Mishina,et al.  Wnt Inhibitors Dkk1 and Sost Are Downstream Targets of BMP Signaling Through the Type IA Receptor (BMPRIA) in Osteoblasts , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[43]  J. Puzas,et al.  Axin2 controls bone remodeling through the β-catenin–BMP signaling pathway in adult mice , 2009, Journal of Cell Science.

[44]  J. Axelrod,et al.  Planar cell polarity signaling: the developing cell's compass. , 2009, Cold Spring Harbor perspectives in biology.

[45]  T. He,et al.  BMP‐9‐induced osteogenic differentiation of mesenchymal progenitors requires functional canonical Wnt/β‐catenin signalling , 2009, Journal of cellular and molecular medicine.

[46]  Qing-yang Huang,et al.  The -9247 T/C polymorphism in the SOST upstream regulatory region that potentially affects C/EBPalpha and FOXA1 binding is associated with osteoporosis. , 2009, Bone.

[47]  Debbie Y. Dao,et al.  Axin2 regulates chondrocyte maturation and axial skeletal development , 2009, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[48]  Xi He,et al.  Wnt/beta-catenin signaling: components, mechanisms, and diseases. , 2009, Developmental cell.

[49]  B. Komm,et al.  Secreted frizzled related protein 1 is a target to improve fracture healing , 2009, Journal of cellular physiology.

[50]  B. Komm,et al.  A small molecule inhibitor of the Wnt antagonist secreted frizzled-related protein-1 stimulates bone formation. , 2009, Bone.

[51]  B. Frenkel,et al.  Lef1 Haploinsufficient Mice Display a Low Turnover and Low Bone Mass Phenotype in a Gender- and Age-Specific Manner , 2009, PloS one.

[52]  R. Fodde,et al.  Adenomatous polyposis coli-mediated control of β-catenin is essential for both chondrogenic and osteogenic differentiation of skeletal precursors , 2009, BMC Developmental Biology.

[53]  Qing Chen,et al.  Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[54]  David M. Thomas,et al.  Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. , 2009, The Journal of clinical investigation.

[55]  Luke H. Hoeppner,et al.  Wnt signaling as a therapeutic target for bone diseases , 2009, Expert opinion on therapeutic targets.

[56]  J. Shaughnessy,et al.  Inhibiting Dickkopf‐1 (Dkk1) Removes Suppression of Bone Formation and Prevents the Development of Osteolytic Bone Disease in Multiple Myeloma , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[57]  G. Omrani,et al.  Lithium's effect on bone mineral density. , 2009, Bone.

[58]  G. Welmaker,et al.  Modulation of Wnt signaling through inhibition of secreted frizzled-related protein I (sFRP-1) with N-substituted piperidinyl diphenylsulfonyl sulfonamides. , 2009, Journal of medicinal chemistry.

[59]  R. O’Keefe,et al.  Activation of β‐Catenin Signaling in Articular Chondrocytes Leads to Osteoarthritis‐Like Phenotype in Adult β‐Catenin Conditional Activation Mice , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[60]  Y. Mishina,et al.  BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway , 2008, Development.

[61]  K. Ozono,et al.  Lrp6 Hypomorphic Mutation Affects Bone Mass Through Bone Resorption in Mice and Impairs Interaction With Mesd , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[62]  R. Nusse,et al.  Alternative Wnt Signaling Is Initiated by Distinct Receptors , 2008, Science Signaling.

[63]  Jie J. Zheng,et al.  Characterization of the Kremen-binding Site on Dkk1 and Elucidation of the Role of Kremen in Dkk-mediated Wnt Antagonism* , 2008, Journal of Biological Chemistry.

[64]  Xi He,et al.  DKK1 Antagonizes Wnt Signaling without Promotion of LRP6 Internalization and Degradation* , 2008, Journal of Biological Chemistry.

[65]  P. Kostenuik,et al.  Targeted Deletion of the Sclerostin Gene in Mice Results in Increased Bone Formation and Bone Strength , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[66]  D. Durant,et al.  Notch inhibits osteoblast differentiation and causes osteopenia. , 2008, Endocrinology.

[67]  P. Bianco,et al.  Mesenchymal stem cells: revisiting history, concepts, and assays. , 2008, Cell stem cell.

[68]  G. Mundy,et al.  Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. , 2008, Blood.

[69]  R. Higgs,et al.  Changes in Osteoblast, Chondrocyte, and Adipocyte Lineages Mediate the Bone Anabolic Actions of PTH and Small Molecule GSK‐3 Inhibitor , 2007, Journal of cellular biochemistry.

[70]  N. Munshi,et al.  Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. , 2007, Blood.

[71]  Kunihiro Matsumoto,et al.  A histone lysine methyltransferase activated by non-canonical Wnt signalling suppresses PPAR-γ transactivation , 2007, Nature Cell Biology.

[72]  Kozo Nakamura,et al.  GSK-3β Controls Osteogenesis through Regulating Runx2 Activity , 2007, PloS one.

[73]  S. Amar,et al.  Inhibition of SFRP1 Reduces Severity of Periodontitis , 2007, Journal of dental research.

[74]  S. Goldstein,et al.  Bone mass is inversely proportional to Dkk1 levels in mice. , 2007, Bone.

[75]  B. Alman,et al.  Beta-Catenin Signaling Plays a Disparate Role in Different Phases of Fracture Repair: Implications for Therapy to Improve Bone Healing , 2007, PLoS medicine.

[76]  I. Gérin,et al.  Wnt Signaling Stimulates Osteoblastogenesis of Mesenchymal Precursors by Suppressing CCAAT/Enhancer-binding Protein α and Peroxisome Proliferator-activated Receptor γ* , 2007, Journal of Biological Chemistry.

[77]  A. Montag,et al.  Distinct roles of bone morphogenetic proteins in osteogenic differentiation of mesenchymal stem cells , 2007, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[78]  C. Cooper,et al.  Lithium use and the risk of fractures. , 2007, Bone.

[79]  J. Devogelaer,et al.  Novel LRP5 Missense Mutation in a Patient With a High Bone Mass Phenotype Results in Decreased DKK1‐Mediated Inhibition of Wnt Signaling* , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[80]  R. Moon,et al.  Chibby Promotes Adipocyte Differentiation through Inhibition of β-Catenin Signaling , 2007, Molecular and Cellular Biology.

[81]  Jayaram Radhakrishnan,et al.  LRP6 Mutation in a Family with Early Coronary Disease and Metabolic Risk Factors , 2007, Science.

[82]  Bart Barlogie,et al.  Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. , 2007, Blood.

[83]  Georg Schett,et al.  Dickkopf-1 is a master regulator of joint remodeling , 2007, Nature Medicine.

[84]  P. Polakis The many ways of Wnt in cancer. , 2007, Current opinion in genetics & development.

[85]  B. Alman,et al.  β-Catenin Signaling Pathway Is Crucial for Bone Morphogenetic Protein 2 to Induce New Bone Formation* , 2007, Journal of Biological Chemistry.

[86]  Xi He,et al.  LRP5 Mutations Linked to High Bone Mass Diseases Cause Reduced LRP5 Binding and Inhibition by SOST* , 2006, Journal of Biological Chemistry.

[87]  D. Kimelman,et al.  β-Catenin destruction complex: insights and questions from a structural perspective , 2006, Oncogene.

[88]  Scott Saunders,et al.  Bone Density Ligand, Sclerostin, Directly Interacts With LRP5 but Not LRP5G171V to Modulate Wnt Activity , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[89]  P. Kostenuik,et al.  Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. , 2006, Bone.

[90]  P. Chuang,et al.  Wnt/β-catenin signaling interacts differentially with Ihh signaling in controlling endochondral bone and synovial joint formation , 2006, Development.

[91]  A. McMahon,et al.  Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors , 2006, Development.

[92]  A. Duval,et al.  TCF-4 isoforms absent in TCF-4 mutated MSI-H colorectal cancer cells colocalize with nuclear CtBP and repress TCF-4-mediated transcription , 2006, Oncogene.

[93]  B. Komm,et al.  Secreted frizzled related protein 1 regulates Wnt signaling for BMP2 induced chondrocyte differentiation , 2006, Journal of cellular physiology.

[94]  T. Clemens,et al.  A Dishevelled-1/Smad1 Interaction Couples WNT and Bone Morphogenetic Protein Signaling Pathways in Uncommitted Bone Marrow Stromal Cells* , 2006, Journal of Biological Chemistry.

[95]  R. Baron,et al.  Deletion of a Single Allele of the Dkk1 Gene Leads to an Increase in Bone Formation and Bone Mass , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[96]  T. Engler,et al.  Orally Bioavailable GSK‐3α/β Dual Inhibitor Increases Markers of Cellular Differentiation In Vitro and Bone Mass In Vivo , 2006 .

[97]  R. Moon Faculty Opinions recommendation of Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. , 2006 .

[98]  O. MacDougald,et al.  Regulation of bone mass by Wnt signaling. , 2006, The Journal of clinical investigation.

[99]  A. Montag,et al.  CCN1/Cyr61 Is Regulated by the Canonical Wnt Signal and Plays an Important Role in Wnt3A-Induced Osteoblast Differentiation of Mesenchymal Stem Cells , 2006, Molecular and Cellular Biology.

[100]  Ian Smyth,et al.  Human sebaceous tumors harbor inactivating mutations in LEF1 , 2006, Nature Medicine.

[101]  R. Nusse,et al.  Purified Wnt5a Protein Activates or Inhibits β-Catenin–TCF Signaling Depending on Receptor Context , 2006, PLoS biology.

[102]  E. Canalis,et al.  Notch 1 Overexpression Inhibits Osteoblastogenesis by Suppressing Wnt/β-Catenin but Not Bone Morphogenetic Protein Signaling* , 2006, Journal of Biological Chemistry.

[103]  R. Baron,et al.  Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[104]  Janet L Stein,et al.  Canonical WNT Signaling Promotes Osteogenesis by Directly Stimulating Runx2 Gene Expression* , 2005, Journal of Biological Chemistry.

[105]  Xi He,et al.  SOST Is a Ligand for LRP5/LRP6 and a Wnt Signaling Inhibitor* , 2005, Journal of Biological Chemistry.

[106]  P. Vestergaard,et al.  Reduced Relative Risk of Fractures Among Users of Lithium , 2005, Calcified Tissue International.

[107]  Bart O. Williams,et al.  Essential Role of β-Catenin in Postnatal Bone Acquisition* , 2005, Journal of Biological Chemistry.

[108]  Minrong Ai,et al.  Reduced Affinity to and Inhibition by DKK1 Form a Common Mechanism by Which High Bone Mass-Associated Missense Mutations in LRP5 Affect Canonical Wnt Signaling , 2005, Molecular and Cellular Biology.

[109]  P. ten Dijke,et al.  SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. , 2005, Cytokine & growth factor reviews.

[110]  Peng Liu,et al.  Sclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling* , 2005, Journal of Biological Chemistry.

[111]  Xizhi Guo,et al.  Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. , 2005, Developmental cell.

[112]  D. Lacombe,et al.  LRP5 mutations in osteoporosis-pseudoglioma syndrome and high-bone-mass disorders. , 2005, Joint, bone, spine : revue du rhumatisme.

[113]  Walter Birchmeier,et al.  Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. , 2005, Developmental cell.

[114]  Hans Clevers,et al.  Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. , 2005, Developmental cell.

[115]  D. Ovcharenko,et al.  Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. , 2005, Genome research.

[116]  W. Birchmeier,et al.  The role of Axin2 in calvarial morphogenesis and craniosynostosis , 2005, Development.

[117]  A. Montag,et al.  Connective Tissue Growth Factor (CTGF) Is Regulated by Wnt and Bone Morphogenetic Proteins Signaling in Osteoblast Differentiation of Mesenchymal Stem Cells* , 2004, Journal of Biological Chemistry.

[118]  M. Bouxsein,et al.  Decreased BMD and Limb Deformities in Mice Carrying Mutations in Both Lrp5 and Lrp6 , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[119]  Matthias B. Wahl,et al.  Skeletal defects in ringelschwanz mutant mice reveal that Lrp6 is required for proper somitogenesis and osteogenesis , 2004, Development.

[120]  R. Nusse,et al.  The Wnt signaling pathway in development and disease. , 2004, Annual review of cell and developmental biology.

[121]  Laurie E Ailles,et al.  Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. , 2004, The New England journal of medicine.

[122]  L. Southam,et al.  Functional variants within the secreted frizzled-related protein 3 gene are associated with hip osteoarthritis in females. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[123]  I. Thesleff,et al.  Mutations in AXIN2 cause familial tooth agenesis and predispose to colorectal cancer. , 2004, American journal of human genetics.

[124]  A. Tarnawski,et al.  Deoxycholic acid activates beta-catenin signaling pathway and increases colon cell cancer growth and invasiveness. , 2004, Molecular biology of the cell.

[125]  Gary S Stein,et al.  The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice. , 2004, Molecular endocrinology.

[126]  E. Canalis,et al.  Notch 1 impairs osteoblastic cell differentiation. , 2003, Endocrinology.

[127]  John A Latham,et al.  Osteocyte control of bone formation via sclerostin, a novel BMP antagonist , 2003, The EMBO journal.

[128]  Roland Baron,et al.  BMP‐2 Controls Alkaline Phosphatase Expression and Osteoblast Mineralization by a Wnt Autocrine Loop , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[129]  Yoshiaki Kawano,et al.  Secreted antagonists of the Wnt signalling pathway , 2003, Journal of Cell Science.

[130]  J. A. Robinson,et al.  High Bone Mass in Mice Expressing a Mutant LRP5 Gene , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[131]  Richard W. Carthew,et al.  Chibby, a nuclear β-catenin-associated antagonist of the Wnt/Wingless pathway , 2003, Nature.

[132]  L. Hofbauer,et al.  High bone density due to a mutation in LDL-receptor-related protein 5. , 2002, The New England journal of medicine.

[133]  Christof Niehrs,et al.  Kremen proteins are Dickkopf receptors that regulate Wnt/β-catenin signalling , 2002, Nature.

[134]  Richard P Lifton,et al.  High bone density due to a mutation in LDL-receptor-related protein 5. , 2002, The New England journal of medicine.

[135]  Ivan Lobov,et al.  Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor , 2002, The Journal of cell biology.

[136]  K. Lindpaintner,et al.  Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease , 2002, Journal of medical genetics.

[137]  Miikka Vikkula,et al.  LDL Receptor-Related Protein 5 (LRP5) Affects Bone Accrual and Eye Development , 2001, Cell.

[138]  Stuart A. Aaronson,et al.  Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow , 2001, Nature Cell Biology.

[139]  M Dioszegi,et al.  Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). , 2001, Human molecular genetics.

[140]  William C. Skarnes,et al.  An LDL-receptor-related protein mediates Wnt signalling in mice , 2000, Nature.

[141]  J. Nathans,et al.  A new secreted protein that binds to Wnt proteins and inhibits their activites , 1999, Nature.

[142]  Elaine Fuchs,et al.  A common human skin tumour is caused by activating mutations in β-catenin , 1999, Nature Genetics.

[143]  J. Nathans,et al.  A Member of the Frizzled Protein Family Mediating Axis Induction by Wnt-5A , 1997, Science.

[144]  K. Kinzler,et al.  Lessons from Hereditary Colorectal Cancer , 1996, Cell.

[145]  F. Masiarz,et al.  Association of the APC gene product with beta-catenin. , 1993, Science.

[146]  K. Kinzler,et al.  Association between wild type and mutant APC gene products. , 1993, Cancer research.

[147]  K. Kinzler,et al.  Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. , 1991, Science.

[148]  S. Altschul,et al.  Identification of FAP locus genes from chromosome 5q21. , 1991, Science.

[149]  Harold E. Varmus,et al.  Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome , 1982, Cell.

[150]  N. Selvamurugan,et al.  MicroRNAs: Synthesis, Gene Regulation and Osteoblast Differentiation. , 2013, Current issues in molecular biology.

[151]  J. Riancho,et al.  Wnt receptors, bone mass, and fractures: gene-wide association analysis of LRP5 and LRP6 polymorphisms with replication. , 2011, European journal of endocrinology.

[152]  T. He,et al.  The therapeutic potential of the Wnt signaling pathway in bone disorders. , 2011, Current molecular pharmacology.

[153]  R. Bhat,et al.  Modulation of Wnt signaling through inhibition of secreted frizzled-related protein I (sFRP-1) with N-substituted piperidinyl diphenylsulfonyl sulfonamides: part II. , 2010, Bioorganic & medicinal chemistry.

[154]  A. McMahon,et al.  Noncanonical Wnt signaling through G protein-linked PKCdelta activation promotes bone formation. , 2007, Developmental cell.

[155]  T. Martin,et al.  Orally bioavailable GSK-3alpha/beta dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo. , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[156]  M. Bouxsein,et al.  Essential role of beta-catenin in postnatal bone acquisition. , 2005, The Journal of biological chemistry.

[157]  T. Ishida,et al.  Cytoplasmic and/or nuclear staining of beta-catenin is associated with lung metastasis , 2004, Clinical & Experimental Metastasis.

[158]  M. Kühl The WNT/calcium pathway: biochemical mediators, tools and future requirements. , 2004, Frontiers in bioscience : a journal and virtual library.

[159]  R. Moon,et al.  Chibby, a nuclear beta-catenin-associated antagonist of the Wnt/Wingless pathway. , 2003, Nature.

[160]  Christof Niehrs,et al.  Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling. , 2002, Nature.

[161]  Mark L. Johnson,et al.  A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. , 2002, American journal of human genetics.